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Schistosomiasis is a water borne parasitic disease of global importance and with ongoing control the disease
endemic landscape is changing. In sub-Saharan Africa, for example, the landscape is becoming ever more
heterogeneous as there are several species of Schistosoma that respond in different ways to ongoing preventive
chemotherapy and the inter-sectoral interventions currently applied. The major focus of preventive chemotherapy is
delivery of praziquantel by mass drug administration to those shown to be, or presumed to be, at-risk of infection
and disease. In some countries, regional progress may be uneven but in certain locations there are very real
prospects to transition from control into interruption of transmission, and ultimately elimination. To manage this
transition requires reconsideration of some of the currently deployed diagnostic tools used in surveillance and
downward realignment of existing prevalence thresholds to trigger mass treatment. A key challenge will be
maintaining and if possible, expanding the current donation of praziquantel to currently overlooked groups, then
judging when appropriate to move from mass drug administration to selective treatment. In so doing, this will
ensure the health system is adapted, primed and shown to be cost-effective to respond to these changing disease
dynamics as we move forward to 2020 targets and beyond.
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Introduction
Schistosomiasis is a waterborne infection and is one of
the most common parasitic diseases in the world, and is
of public health global importance [1]. This disease has
major health and socio-economic repercussions, and
constitutes an important public health problem in devel-
oping countries as well as a significant hazard for visi-
tors and travellers who visit disease endemic regions.
Human schistosomiasis is caused by six species of* Correspondence: tchuemtchuente@schisto.com
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S. japonicum, S. mekongi, S. intercalatum and S. guineen-
sis; and is endemic in 78 countries [1, 2]. Of these six
species, S. haematobium is responsible for urogenital
schistosomiasis and has significant interactions with
HIV and also HPV [3], whilst other species each cause
intestinal or rectal schistosomiasis. It is estimated that
779 million people are at risk of infection, and about
250 million people are currently infected [2, 4]. The Glo-
bal Burden of Disease study of 2010 attributed some
3.31 million disability-adjusted life years (DALYs) and 11
700 death per year to schistosomiasis, a mortality figure
which has been challenged as a gross underestimate [5].
Schistosomiasis affects the poorest of the poor and in-
fections are particularly abundant among people living
in rural or deprived urban or peri-urban settings [6].
These populations typically have low socio-economic
status with limited access to clean water and with inad-
equate sanitation provision [7, 8]. The morbidity causedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Tchuem Tchuenté et al. Infectious Diseases of Poverty  (2017) 6:42 Page 2 of 14by schistosomes is commonly associated with moderate-
to-heavy egg-infection intensities and is progressive; as
compared with any other age group, school-aged chil-
dren and pre-school children are the most vulnerable
groups to developing overt disease [9, 10]. These groups
typically harbour the largest numbers of adult worms,
with copious tissue entrapped eggs causing systematic
and organ-specific inflammation, concomitantly when
the consequences of this infection causes greatest
physiological and developmental insult [2]. Studies have
demonstrated that children can acquire schistosome in-
fections within the first few months of life [11, 12], caus-
ing early life initial organ damage and altered
development, mediated by fibrotic lesions around tissue-
trapped eggs, manifesting overtly in adolescence and
early adulthood [9, 13].
Successful schistosomiasis control programmes in
Japan, China, Philippines, Brazil, Egypt and in some sub-
Saharan African countries have shown that control of
schistosomiasis with progression towards elimination of
disease is feasible [14]. The recent impetus for schisto-
somiasis control has generated a greater political com-
mitment, as well as an unprecedented opportunity for
cost-effective action [15, 16]. This momentum has en-
couraged many countries to establish national action
plans and programmes to control neglected tropical dis-
eases (NTDs) [7, 17, 18].
Within the past decade, significant progress has been
made on large scale treatments through integrated con-
trol of schistosomiasis and other NTDs, thanks to a
number of international organizations, donor founda-
tions, bilateral institutions and non-governmental orga-
nizations that responded to the WHO’s 2001 call for
action [19]. Today, treatment with praziquantel [20] is
cost-effective and ‘preventive chemotherapy’ is currently
the strategy of choice and endorsed by WHO [9, 21].
With a support from the USAID and the UK Depart-
ment for International Development (DFID), as well as
the Bill and Melinda Gates Foundation, the pharmaceut-
ical industry, and several not-for profit organizations,
millions of children are regularly treated for schistosom-
iasis and other NTDs simultaneously, through coordi-
nated use of anthelminthic drugs [22, 23].
In the past, a key bottleneck to implementation of pre-
ventive chemotherapy for control of schistosomiasis in
sub-Saharan Africa was the limited access to praziquan-
tel, either purchased or donated [24]. From 2002, with
the expansion of activities of the Schistosomiasis Control
Initiative, it was clear that the future need for large-scale
quantities of praziquantel would grow [18]. In 2007,
Merck KGaA pledged to donate 200 million tablets of
praziquantel over 10 years through WHO. However, in
2012, Merck-KGaA committed to increase its donation
to 250 million tablets of praziquantel per year untilschistosomiasis is eliminated. To bolster this donation,
additional amounts of praziquantel and resources for
implementation were provided by other partners. Whilst
there is now growing access to praziquantel for schisto-
somiasis control in sub-Saharan Africa, it is not at the
level of projected requirements to reach all people at
risk and requiring treatment [25]. Analysis of data re-
ported on treatment coverage for schistosomiasis show
that utilization of available praziquantel by NTD pro-
grammes is not yet optimal in many countries [22, 23].
Furthermore, special attention is needed to develop new
access plans and reporting frameworks to vulnerable demo-
graphic groups in high-risk areas, particularly pre-school-
aged children who are currently overlooked [10, 26].
However, the control of schistosomiasis is a long-term
undertaking which involves several challenges. Current
strategies were designed primarily for the control of
morbidity due to schistosomiasis and were formulated
over two decades ago when the availability of praziquan-
tel was limited [27, 28]. The new impetus towards schis-
tosomiasis elimination requires some modification,
adaptation and even change of strategies [14, 29, 30],
which concomitantly raises new challenges and points
for consideration [31, 32]. This paper highlights the pro-
gress made and reviews the main challenges and require-
ments to move from control to elimination of
schistosomiasis in sub-Saharan Africa.
Schistosomiasis and the global health agenda
In 1975, the World Health Assembly (WHA) adopted
the WHA 28.53 resolution calling for the preparation of
guidelines and increased efforts in drug development,
water projects and partner mobilization for schistosom-
iasis control [27]. The following year, in 1976, the
WHA29.58 resolution urged endemic countries to con-
sider the epidemiological aspects of schistosomiasis
when planning and implementing water management
schemes, and to undertake specific measures to prevent
the spread of the disease into new areas and neighboring
countries [33]. However, despite the existence of tools in
the 1970s and 1980s, control of schistosomiasis was
only sustained for a prolonged period in a few coun-
tries and almost no progress was made in sub-
Saharan African countries, the most endemic part of
the world. In the 1990s, interest in the control of
schistosomiasis in Africa waned, and disease control
was overshadowed by other health priorities [34]
through an era of health sector reform and World
Bank driven Structural Adjustment Programmes.
Recent years have witnessed an increased interest in
the control/elimination of NTDs, and today the control
of schistosomiasis has again become a priority on the
agenda of many governments, donors, pharmaceutical
companies and international agencies. This has been
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member states of WHO endorsed the WHA54.19 reso-
lution on schistosomiasis and STH, with the major ob-
jective of the regular treatment of at least 75% of all
school-aged children at risk of morbidity by 2010 [28].
This resolution generated a greater political commit-
ment and encouraged many countries to establish na-
tional action plans and programmes for schistosomiasis
and STH control. Ten years later, in January 2012,
WHO published an NTD Roadmap that set targets for
the period 2012–2020, and described the strategic ap-
proach to accelerate work to overcome the global impact
of NTDs. This roadmap identified preventive chemo-
therapy as a key strategy for tackling NTDs which
responded to mass chemotherapy [21, 35]. At the same
time (January 2012), partners and stakeholders (pharma-
ceutical companies, donors, endemic countries, Non-
Governmental Organizations) endorsed the London dec-
laration on NTDs, and committed to support the WHO
roadmap and its 2020 targets for 10 NTDs. In response,
the pharmaceutical sector committed to donate all re-
quired drugs for as long as necessary [36].
Still in 2012, WHO member states endorsed the
WHA65.21 resolution on elimination of schistosomiasis,
that called on all endemic countries to intensify control
interventions and strengthen surveillance. Importantly,
this resolution urged countries to embark on schisto-
somiasis elimination where possible [35]. This change of
policy was a bold and important step towards the elim-
ination of schistosomiasis. Finally, in 2013, the
WHA66.12 resolution on NTDs urged countries to en-
sure continued country ownership of programmes for
NTD prevention, control, elimination and eradication;
to further strengthen disease surveillance system; to ex-
pand and implement appropriate interventions against
NTDs; to advocate for funding; to strengthen capacity
for NTD prevention, control, monitoring and evaluation;
to devise plans for achieving and maintaining universal
access to and coverage with interventions against NTDs,
including provision of safe drinking-water, basic sanita-
tion, health promotion and education [1].
Clean water provision, sanitation and hygiene (WASH)
are critical components in the prevention and care for
all NTDs scheduled for intensified control or elimination
by 2020. For schistosomiasis, improved sanitation across
the entire community to prevent contaminated faeces
and urine from reaching surface water can reduce or
eliminate transmission, by stopping worm eggs in faeces
and urine from entering water–the snail habitat.
Provision of safe water, sanitation and hygiene is one of
the five key interventions within the global NTD road-
map. This requires a strong intersectoral collaboration.
WASH providers must prioritize reduction of inequal-
ities to align with the Sustainable Development Goals’agenda, as developed in the recent WASH strategy to
accelerate and sustain progress on NTDs [37].
The WHO NTD roadmap set three time-bound goals
for the control or elimination of schistosomiasis. First,
2015 for the elimination of schistosomiasis in the East-
ern Mediterranean Region, the Caribbean, Indonesia and
the Mekong River basin. Second, 2020 for schistosomia-
sis elimination in the Americas and Western Pacific Re-
gions; and potential elimination as a “public health
problem” in multiple countries in Africa. Although
schistosomiasis was not yet scheduled for elimination in
sub-Saharan Africa by 2020, the roadmap envisaged po-
tential elimination in selected countries or parts of
countries where conditions were appropriate, such as
Zanzibar (United Republic of Tanzania) where a con-
certed effort was on-going (SCORE project and China-
Africa initiative). Finally, the roadmap set a potential
global elimination of schistosomiasis as a “public health
problem” by 2025 [1, 31, 36].Progress in the control of schistosomiasis in SSA
A key aspect within the WHO Roadmap was making the
burden of schistosomiasis much more explicit which
then allowed calculation and forecasting of future prazi-
quantel requirements for each country. There has been
substantial progress towards WHO Roadmap goals for
schistosomiasis and regional targets, as the control of
schistosomiasis has become a priority on the agenda of
many governments. This momentum has encouraged
many countries to establish national action plans and
programmes to control NTDs [7, 17, 38]. By 2016, 36
African countries had developed and launched their na-
tional NTD master plans. With a support from USAID
and UK Department of International Development
(DFID) governments, as well as the Bill and Melinda
Gates Foundation, the pharmaceutical industry, and
many not-for profit organizations, the mapping of NTDs
has been completed and millions of children are regu-
larly treated for schistosomiasis and other NTDs.Mapping the schistosomiasis distribution
Although the African region bears a disproportionately
high burden of schistosomiasis, the mapping of disease
prevalence remained incomplete in many countries. In
January 2014, the WHO Regional Office for Africa
(AFRO) launched a mapping initiative targeting to the
completion of the mapping of the five NTDs amenable to
preventive chemotherapy (lymphatic filariasis, onchocer-
ciasis, schistosomiasis, STH and trachoma) in all countries
of the African region. Funded by the Bill and Melinda
Gates Foundation, this project enabled the acceleration of
the completion of Preventive Chemotherapy amenable
NTD mapping in the WHO African region.
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strong WHO AFRO support, the deployment of a
pool of well-trained NTD expert and mapping spe-
cialists, and a strong commitment by governments,
significant progress has been made in the mapping of
PC NTDs in the African region within the past 3
years. By June 2016, mapping of PC NTDs, including
schistosomiasis, was completed in 41 countries of the
47 countries of the WHO African region, and there
remained only six countries where mapping was still
ongoing: Algeria, Angola, Central Africa Republic,
Ethiopia, South Africa, and South Sudan [39]. This
achievement was a critical step to enable the com-
mencement of interventions towards the 2020/2025
schistosomiasis control and elimination targets.
Treatment
Considerable progress is being made in scaling-up pre-
ventive chemotherapy interventions in sub-Saharan Af-
rica. With a support from USAID, DFID, BMGF, the
pharmaceutical industry and many not for profit organi-
zations, millions of children are regularly treated for
schistosomiasis and other NTDs. Within the past 10
years, the number of people treated for schistosomiasis
in the WHO African region has significantly increased
from about 7 million in 2006 to more than 52 million in
2014, corresponding to a scaling up of coverage from
5.47% in 2006 to 20.13% in 2014 [23].
In the more recent report on schistosomiasis treat-
ment worldwide, WHO estimated that the total number
of people requiring treatment for schistosomiasis in
2015 was 218 700 000 (vs 258 875 452 in 2014), of
whom 92.04% lived in the African Region. Reports on
the annual progress on preventive chemotherapy inter-
ventions received in WHO by 20 September 2016 re-
vealed that 27 African countries (vs 23 in 2014) hadFig. 1 Evolution of the number of people treated for schistosomiasis and t
and 2015reported their treatment data for 2015 by then. From
this interim report, the number of people treated in the
Region was 57 400 000 in 2015 compared to 52 413 796
in 2014 and 26 489 501 in 2013. The number of school-
age children that received treatment for schistosomiasis
in 2015 was 46 600 000 (vs 43 725 454 in 2014), repre-
senting 81.2% of the total number of people treated in
the African region [22, 23, 40]. Figure 1 illustrates the
steady progress in schistosomiasis treatment in Africa
since 2006. The increase of the number of treatments
could be explained by several factors: the increased sup-
ply of praziquantel essentially from the Merck KGaA do-
nation, new countries starting to implement preventive
chemotherapy for schistosomiasis, geographical scale up
of the treatment within countries and an improvement
in the reporting.
The summary of the global update of preventive
chemotherapy implementation in 2015 revealed a signifi-
cant improvement in the treatment coverage, reaching
for schistosomiasis up to 41.8 and 40.8% for school-aged
children at the global and African regional levels, re-
spectively. However, we are still very far from the target,
and there is a need to strengthen programme perfor-
mances to scale-up the preventive implementation and
increase the coverage.
Challenges and requirements
Moving from control to elimination of schistosomiasis is
a paradigm shift that creates several challenges. Current
interventions and strategies were designed for morbidity
control or the elimination of schistosomiasis as a “public
health problem” [9, 29]. The interruption of schistosom-
iasis transmission is a long-term undertaking but re-
quires significant changes in the approach, design and
strategies with a focus on reducing transmission and
preventing reinfection. This involves several challengesreatment coverage in the WHO African region, between 2006
Tchuem Tchuenté et al. Infectious Diseases of Poverty  (2017) 6:42 Page 5 of 14such as implementation of intensified interventions, ex-
pansion of treatment coverage, use of alternative strat-
egies, improvement of clean water supply, sanitation and
hygiene, health education, funding for interventions,
monitoring and evaluation, and strengthening of institu-
tional capacities and surveillance response system. The
present analysis highlights some of the key challenges
and requirements for schistosomiasis elimination in sub-
Saharan Africa.
Moving from MDA focused intervention to
complementary public-health interventions
The ultimate goal of all schistosomiasis intervention efforts
should be the elimination of this infection. Several pro-
grammatic steps are recognized for the control and elimin-
ation of schistosomiasis [14]. These steps require specific
interventions, including interventions for morbidity control
and those for infection prevention. It is recommended that
schistosomiasis endemic countries progressively scale-up
their objective from control of morbidity to elimination as
a public health problem, and finally interruption of trans-
mission. While moving through these steps, activities
should be reorganized gradually. Currently, morbidity con-
trol is the objective in many countries and interventions are
limited to chemotherapy with praziquantel [23, 41]. How-
ever, it is known that treatment alone will not be sufficient
to achieve the interruption of schistosomiasis transmission
[42]. Therefore, if the elimination goals for schistosomiasis
are to be met, endemic countries should adopt a final push
approach combining intensified preventive chemotherapy
and the implementation of complementary public-health,
environmental and educational interventions. Such intensi-
fied preventive chemotherapy consists of implementing the
distribution of praziquantel more frequently, and/or to ex-
tend the treatment to population groups that are different
than those targeted so far [31, 32].
Complementary public-health interventions include
health education for behaviour change, provision of safe
water and sanitation, environmental management and
snail control. This combined approach is recommended
in areas approaching elimination as a public-health
problem, and is essential when interruption of transmis-
sion is at the objective. In the Regional Strategic Plan for
schistosomiasis, WHO/AFRO defined this approach as
PHASE, standing for preventive chemotherapy, health
education, access to clean water, sanitation improve-
ment, and environmental snail control and focal mollus-
ciciding [14]. Increasing access to safe water is an
intervention that will significantly reduce the risk of
schistosomiasis transmission. Its achievement requires
inter-sectoral collaboration and partnership. However,
most countries cannot raise the resources required to
drastically increase safe water supply. Thus, in most
schistosomiasis endemic countries, natural water bodies(many of which are infested with snails and infective
schistosome cercariae, sometimes of zoonotic origin)
continue to be the only sources of domestic water and
high risk communities cannot avoid reinfections even if
they were effectively treated. A further challenge is to
address the needs of those where occupational exposure
is a daily feature of tending, for example, to agricultural
work and fishery [43].
Poor sanitation is a major contributor to transmission
of schistosomiasis and causes rapid re-infection among
treated children and adults. Improvement in waste dis-
posal and a reduction in open defaecation is essential for
achieving interruption of transmission. Improvement in
sanitation not only contributes to prevention of trans-
mission, but also to the prevention of many diarrhoeal
diseases. Sensitization and mobilization of people to
build and use latrines should be strengthened. There are
two main strategies within WASH that feature participa-
tory hygiene and sanitation transformation (PHAST)
and community-led total sanitation (CLTS), however,
neither of these approaches will effectively reduce the
contamination of water sources by schistosome eggs in
the urine. Environmental management for snail control
has not been generally undertaken in the sub-Saharan
African region due to cost limitations and lack of identi-
fication of the water bodies where this is feasible. As
snail control is generally challenging especially in large
water bodies, there is need to identify areas with high
water contact and intensive schistosomiasis transmission
so that targeted snail control can be limited to such loca-
tions. However, technical capacity and funding to imple-
ment reliable snail surveys is lacking in many countries. In
China, new and effective snail control approaches, envir-
onmental modification (i.e. alteration of the ecological en-
vironments of the snails’ habitats to make their survival
difficult) have been developed and adapted to the local
situation in snail-infested areas. The current China-Africa
cooperation for schistosomiasis elimination provides a
platform to learn from Chinese experiences, in the control
of intermediate snail hosts [44].
Scaling up treatment
Although significant progress has been made over the
recent years to regularly implement MDA in several
countries, the global achievement is still distant from the
WHO’s target of regular deworming of at least 75% of
school-age children at risk. Indeed, it is estimated that
the global coverage of schistosomiasis treatment in 2015
was only 28% [40]. In many countries, school-based
deworming interventions still cover only a minority of
children considered to be at risk despite the low cost of
preventive chemotherapy and their significant impact on
health. Despite the increase in drug donation, the major
constraint to controlling schistosomiasis continues to be
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tries have reached the target threshold treatment of at least
75% of school-age children in the African Region [40].
To reach the schistosomiasis elimination target, there
is an urgent need to accelerate the extent of treatment
to reach all individuals at risk. This extension of prevent-
ive treatment for schistosomiasis remains a serious chal-
lenge, and should be conducted at several levels. First,
there is a need to accelerate the scaling up of mass drug
administration to reach 100% geographical coverage and
at least 75% of school-aged children in all endemic
countries in the African region. This include a challenge
to tackle the big countries such as Nigeria, Democratic
Republic of Congo, Ethiopia and Tanzania which ac-
count for 60% of at risk population not yet entirely cov-
ered by preventive chemotherapy. Secondly, there is a
need to extend treatment to the maximum number of
out-of-school school-aged children. Children aged 5–14
years, who are the main target group of preventive
chemotherapy, are relatively easily reached through
school based deworming. However, most of out-of-
school children are not reached through this platform.
Special efforts should be made to extend treatment to
this group. Thirdly, there is a need to extend preventive
chemotherapy to adult populations. The available do-
nated drugs are for school-aged children primarily, and
therefore adults, especially high risk populations such as
fishermen, irrigation workers, and women are not
treated during deworming campaigns.
The risk factor of urogenital schistosomiasis for infec-
tion by HIV in women has been clearly demonstrated
[45, 46], and adolescent girls and women therefore re-
quire treatment with praziquantel in areas endemic for
S. haematobium more frequently than in non-endemic
areas, to reduce the risk of development of genital le-
sions. Finally, it becomes urgent to recognize the im-
portance of pre-school age children and their need for
treatment. Although children aged less than 5 years can
be already infected through passive water contacts some-
times at alarming levels [47, 48], they are currently not
targeted by national chemotherapy campaigns because
of a lack of suitable paediatric formulations of prazi-
quantel [10, 26].
It is important to highlight that if the elimination goal
is to be achieved for schistosomiasis, it will be essential
to extend the preventive chemotherapy to all popula-
tions who need treatment, inclusive of pre-school aged
children, school-aged children, as well as adults. Schisto-
somiasis does not just affect school-age children only,
even though they may have the highest prevalence of in-
fection, and possibly the heaviest disease burden. With-
out treatment of all those at risk or contributing to
transmission it is not surprising that treatment limited
to children has limited impact in this regard. Treating allthe community will increase the impact of preventive
chemotherapy, and will allow the reduction of schisto-
some reservoirs in the communities and accelerate the
interruption of parasite transmission.
Reaching hard to reach and vulnerable communities
Today, the coverage of the public-health interventions
recommended by the World Health Organization
against NTDs may be interpreted as a proxy for univer-
sal health coverage and shared prosperity. For schisto-
somiasis, universal health coverage means that all people
in need should benefit from the preventive chemother-
apy and other control/elimination interventions. The
Sustainable Development Goals (SDGs) are reinforced
by the commitment of global leaders to ensure that “no
one is left behind” from development progress over the
next 15 years. However, equity is not currently achieved
for NTDs; hundreds million of the world’s most vulner-
able, most disadvantaged people are still left behind, es-
pecially the poorest of the poor, who live in the
remotest, hardest to reach parts of the countries or the
world.
Hard to reach and vulnerable communities include
communities that are poorly served by local health ser-
vices, roads and transport facilities, itinerant fishing and
nomadic communities, seasonal migrants, peri-urban
settlers and those unwilling to accept health interven-
tions (systematic non compliers). A good example are
the challenges of reaching fishing communities along the
large lakes such as Lake Albert, Lake Victoria and Lake
Malawi that border several countries in Eastern Africa,
including Uganda, Kenya, Tanzania and Malawi [49–51].
There are also areas inadequately covered with prevent-
ive chemotherapy due to civil unrest and conflict as well
as health system crisis caused by recent Ebola outbreak
in West Africa [52, 53].
Adapting treatment to transmission dynamics: the need
for alternative strategies
Schistosomes have a complex life cycle that requires a
freshwater snail intermediate host and a vertebrate de-
finitive host in which the parasites can undergo develop-
ment. This ties transmission to landscapes where people
and snails come together at the same water habitat. The
success of the transmission depends on numerous fac-
tors, including biotic and abiotic features, such as cli-
matic, physical and chemical factors that affect the
survival and development of schistosome parasites and
snail host populations [54] as well as socioeconomic and
behavioural characteristics of the human community
such as water contact behaviour and the adequacy of
water and sanitation, which affect the frequency and in-
tensity of exposure to infected water [55, 56]. The dis-
ease transmission is highly focal, and the endemicity
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from one country to another. It is well known that the
patterns and dynamics of transmission of schistosomiasis
present tremendous complexity and variability between
different foci and even within the same foci. The most
significant determinants being water contact patterns,
sanitation and hygiene levels, and the abundance and
susceptibility of freshwater snail hosts.
The existence of schistosome hotspots–i.e. transmission
areas where prevalence and intensities remain high despite
repeated rounds of mass drug administration–has been
demonstrated in several countries [57, 58]. For example, a
number of villages near Lake Albert have shown to main-
tain very high levels of infection with S. mansoni following
several years of chemotherapy with praziquantel [59].
Similar observations of hotspots infections despite re-
peated treatments have been reported in several other
countries such as Tanzania/Zanzibar, Mali, Kenya, and
Cameroon. In Cameroon, we observed hotspots of trans-
mission in several localities around lakes and dams such
as Barombi Kotto in the South West region and Malan-
touen in the West region, where water contacts are highly
intense and lead to high reinfection patterns. In these foci
the prevalence rapidly returns near to the initial level
within 6–12 months post-treatment (Fig. 2).
To be efficient, preventive chemotherapy should be re-
peated more frequently in such hotspots, at least twiceFig. 2 Intense water contact leading to high transmission dynamics of schistos
South-West region of Cameroon, is divided in two parts; a mainland and an isla
mainland, and illustrates the intense water exposure of populations. There is no
mainland. Therefore, they have contact with water at least twice per day, as the
rapid and high reinfections with schistosomiasis, that occur even from the same
island; the whole population relies on water from the lake, and 100% of people
patterns are significantly different between populations from the island and tho
hotspots that require more regular and intensified interventionsper year. However, the current recommended treatment
strategy does not consider the diversity of transmission
dynamics, reinfection patterns and the special features
of schistosomiasis transmission foci. With the shift to-
wards schistosomiasis elimination, there is a need to
adapt treatment strategies to the different types of trans-
mission settings. Urban schistosomiasis may also require
more intense and frequent interventions.Mapping quality and uncertainties
The mapping of NTDs is a critical step in understanding
where at-risk populations live in order to target effect-
ively available resources and to achieve maximum im-
pact on disease burden [60]. Without reliable mapping
information, countries are not able to plan interventions.
Accurate mapping of disease distribution is therefore a
prerequisite for effective implementation of interven-
tions to reduce the burden of schistosomiasis [57, 58,
61]. Within the past 10 years, significant progress has
been made in the mapping of schistosomiasis in the Af-
rican region, and mapping was completed in about 40
countries. This exercise was supported by various orga-
nizations, funders, partners, and research institutions in
different countries.
In the mapping design for schistosomiasis, the health dis-
trict is the implementation unit, and a subsample of up toomiasis in Barombi Kotto. Barombi Kotto, a village located in the
nd. This photograph shows a view of the island from the shore of the
school in the island. All children leaving in the island go to school in the
y must cross the lake out and in. This frequent water exposure leads to
day of treatment in schools. Furthermore, there is no water supply in the
are at high risk of infections. The transmission dynamics and reinfection
se living on the mainland. Particular attention should be paid to such
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the high focality of schistosomiasis transmission, sub-
districts may be considered in certain circumstances. How-
ever, financial resources being a major constraint, not every
sub-district in a district can be mapped independently. The
mapping design may combine several sub districts into
mapping units, where transmission is likely to be similar,
according to ecological factors affecting schistosomiasis
transmission. This may lead to some uncertainties if the site
selection and sample size are not properly undertaken. In-
deed, selection of schools should be purposive and should
be guided by previous knowledge in the areas where trans-
mission is known, suspected or more likely to occur, such
as proximity to lakes, streams, and water bodies. Schools
should not be selected in the same locality, but selection
should consider geographical distribution of schools in
order to be representative within the health district. Import-
antly, due to the high focality of schistosomiasis transmis-
sion, random selection of schools should be avoided.
However, different approaches were used in some countries
where national surveys were conducted using random se-
lection of schools in health districts, or using remote sens-
ing technologies to predict schistosomiasis distribution.
Studies have demonstrated that using predictive mapping
alone does not provide reliable information for mass drug
administration planning, resulting in overtreatment in some
areas and most importantly under-treatment in areas that
needed it most [62]. This raises concerns about the accur-
acy of various mapping data resulting from less robust
techniques that have been used in several countries.
Because of the highly focal distribution of the disease,
there is a need for more accurate mapping to deepen the
understanding of the distribution of schistosomiasis and
snails in the country, which should guide programme deci-
sion making for mass drug administration. Furthermore,
the maps should be dynamic entities that change with time
as control progresses, necessitating refinement of tools for
updating the original disease maps. As elimination moves
forward there will likely be a need to map more geographic
points, with an optimum to get to all schools within health
unit. Currently mapping level ratio of surveyed to non-
surveyed schools if about 1:10, but recent work in Namibia
using rapid diagnostic tests have decreased to 1:4, so there
is quite a bit more surveillance could be needed when we
are looking for the possibility of any evidence of having
schistosomiasis [57]. Ideally, a knowledge of water contact
sites and an understanding of local transmission should
guide mapping decisions and interventions [63].
Redefining disease endemicity and focality for eligibility
for MDA
The eligibility of health districts for MDA implementa-
tion is determined by the disease endemicity levels
which are generally estimated by the disease prevalence[9]. For each implementation or mapping unit, one
prevalence will be estimated and the entire district will
be classified as non-endemic, low, moderate or high-risk
area. The treatment strategy will be decided based on
this classification. For schistosomiasis, the initial map-
ping is done by collecting stool and/or urine samples in
about five schools per district [64]. The disease preva-
lence of the districts is calculated as the mean preva-
lence of all samples from each district. This district will
then be classified according to the level of this mean
prevalence. Currently, schistosomiasis endemicity maps
are produced on this basis, as well as the subsequent de-
cision to implement preventive chemotherapy or not.
Although this WHO recommended method to esti-
mate district endemicity may have been suitable in the
past, within the context of morbidity control and paucity
of drug availability and funding, it may not be suitable
now elimination is the goal. Indeed, due to the high
focality of schistosomiasis transmission, there may exist
significant difference in infection prevalence between
schools within the same districts. With such a mixture
of low and high prevalence, considering only the mean
prevalence may lead to an underestimation of the dis-
ease occurrence within some districts, resulting to their
exclusion for treatment. For example, a district with one
school having 49% prevalence and four schools exhibit-
ing 0% prevalence each, will have a mean prevalence of
9.8%. As this mean prevalence is below 10%, this district
will be classified on the map as not eligible for mass
drug administration. The consequence would be that in
parts of this districts populations will suffer for schis-
tosomiasis and its morbidity without intervention
from the national authorities. It is therefore necessary
for national programmes to have the detailed distribu-
tion of the disease at the various sub-districts and
schools’ levels to guide treatment decisions and avoid
misclassifications [57, 63].
To assess the impact of the current determination of
endemicity level on treatment decisions, we conducted a
detailed analysis of the recent mapping data in
Cameroon, comparing the estimation of district endem-
icity levels using the mean prevalence in one hand, and
the maximum school prevalence for schistosomiasis per
health district on the other. The results showed that
over the total 189 districts mapped, 47 (24.9%) changed
their endemicity classification when considering either
the mean school prevalence or the higher school preva-
lence. Detailed analysis of these 47 districts revealed that
when considering the mean prevalence, 44.7% of the dis-
tricts (n = 21) had an overall prevalence of <10%, and
should therefore be entirely excluded for mass drug ad-
ministration, despite the fact that in some localities
within these districts there exist high transmission foci,
with a school prevalence up to 52.8%.
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all within the moderate-risk community group when
using the mean prevalence estimates. However, when
using the higher school prevalence, almost all districts
except one (96.2%) changed category, moving from
moderate-risk to high-risk communities.
These results, illustrated in Figs. 3 and 4, suggested
that the current method of estimation of district endem-
icity significantly underestimates the disease transmis-
sion levels, and therefore reduced the treatment
interventions. This underestimation and its impact on
the programme policy decision showed that the way of
determining district endemicity and eligibility to MDA is
not suitable in a context of schistosomiasis elimination
goal, calling for a reassessment of the current policy.
The need to change (the current) treatment thresholds
Because morbidity is typically associated with increasing
worm burden (and entrapment of eggs) rather than the
absence or presence of infection, prevalence is com-
monly combined with worm burden (intensity of infec-
tion) to assess the epidemiological situation for
schistosomiasis. Worm burden is commonly measuredFig. 3 Comparison of district endemicity level/classification using either th
school prevalence within the district (b) in Cameroonby the number of eggs per gram (EPG) of faeces or eggs
per 10 ml of urine [13]. Prevalence and intensity of in-
fections are used to classify communities into transmis-
sion categories, which enables the appropriate approach
to mass treatment in a community [9]. Existing recom-
mendations on frequency of treatment and target popu-
lations (Table 1) were developed with the aim of
controlling morbidity associated with schistosomiasis.
With the paradigm shift from control to elimination of
schistosomiasis, the current recommended treatment
strategy and treatment threshold for interventions is not
compatible with the permanent interruption of transmis-
sion. Furthermore, schistosomiasis is a dynamic disease
and prevalence within communities can change rapidly
from year to year. Thus contamination of a water body
by a few remaining infected individuals can give rise to
outbreaks of disease that need to be quickly contained.
In recent years, the costs of PZQ and the lack of re-
sources were major constraints for the elimination of
schistosomiasis. Today, there is a greater impetus, with
increasing funding opportunities and donated PZQ by
pharmaceutical companies. Time is right to move to-
wards schistosomiasis elimination, and for this challengee mean prevalence of schistosomiasis per district (a) or the higher
Fig. 4 The changing of health district endemicity category for
schistosomiasis in Cameroon, from lower-risk (rose bars) to
moderate-risk (red bars) and high-risk (dark red bars), when moving
from using the current recommended mean district prevalence
(Mean) to using the maximum school prevalence within the district
(Max). The number of districts per category are reported in the
corresponding bars
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vention (i.e. prevalence > 10%) and to define carefully the
implementation unit for PZQ mass drug administration.
Treatment algorithms should be re-defined based on
current knowledge and experiences. WHO has recom-
mended that after achieving morbidity control, prevent-
ive chemotherapy should be appropriately adjusted to
the new epidemiological conditions by lowering the
prevalence risk thresholds. Further, beyond the stage at
which elimination as a public-health problem is
achieved, a more aggressive strategy will be required in
order to attain the more ambitious goal of interrupting
transmission [1]. To achieve this goal as set in the WHOTable 1 Recommended treatment strategy for schistosomiasis in pr
Category Prevalence among school-
aged children







≤30% by questionnaire for
visible haematuria (urinary
schistosomiasis)
Treat all school-age children (en









<30% by questionnaire for
visible haematuria (urinary
schistosomiasis)
Treat all school-age children (en






Treat all school-age children (en
enrolled) twice during their prim
age (e.g. once on entry and onSchistosomiasis Strategic Plan 2012–2020, the preva-
lence of heavy-intensity infections should be reduced to
less than 5% in all schistosomiasis-endemic countries by
2020, and to less than 1% by 2025 [65].
The need for better diagnostic tools
Because of its simplicity and relatively low-cost, the
Kato–Katz technique is widely used for epidemiological
field surveys and is recommended by the WHO for sur-
veillance and monitoring of schistosomiasis control pro-
grammes [66]. Though the specificity is high, the
sensitivity of Kato–Katz in single stool sample examin-
ation is limited by day-to-day variation in egg excretion
rates, thus leading to measurement error in estimating
the presence of infection. This is particularly accentu-
ated in areas with high proportions of light intensity in-
fections [67, 68]. In the current era of preventive
chemotherapy, the intensification of large-scale interven-
tions and repeated mass deworming will significantly re-
duce the prevalence and intensities of schistosome
infections [69]. As a consequence of the increase of low-
intensity infections, less intense infections will be often
missed if single stool samples are examined by Kato–
Katz method, resulting in significant underestimation of
prevalence [67]. Therefore, there is a need to develop
and validate more sensitive diagnostic tools for accurate
surveillance and monitoring of schistosomiasis control
programmes, and for monitoring of drug efficacy. Some
studies recommended multiple stool samples in order to
avoid underestimating the ‘true’ prevalence and trans-
mission potential of the parasite. Indeed, it was demon-
strated that Kato–Katz examination of three instead of
one stool specimen increased the sensitivity of helminth
diagnosis, most notably for hookworm and schistosomes
[70]. However, this has significant cost implications andeventive chemotherapy (WHO, 2006)
rolled and not Also treat adults considered to be at risk (from
special groups to entire communities living in
endemic areas; see Annex 6 for details on special
groups)
rolled and not Also treat adults considered to be at risk (special risk





Praziquantel should be available in dispensaries and
clinics for treatment of suspected cases
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control programmes can easily undertake for multiple
sample collections on different days, at more geograph-
ical sites.
Several alternative diagnostic tools have been tested
for the detection of schistosome infections. The point-
of-care urine-based circulating cathodic antigen (POC-
CCA) test has been reported as more sensitive than Kato
Katz for intestinal schistosomiasis. This test has been
widely applied for the diagnosis of S. mansoni in Africa
[70, 71]. The data from a multi-country study indicated
that the POC-CCA assay can contribute greatly to the
identification of endemic locations, thereby providing a
tool for the more accurate disease mapping needed to
properly plan and cost interventions for control, with
the ultimate objective of moving toward total elimin-
ation [71]. Studies have also demonstrated the higher
sensitivity of the circulating anodic antigen (CAA) com-
pared to Kato Katz or urine analysis alone. However,
higher prevalence obtained with both CCA and CAA
tests argue for the continuation of mass drug adminis-
tration in endemic zones. The high costs to implement
these tests and control interventions may certainly con-
stitute a major constraint. As we move to elimination it
may also be appropriate to move away from MDA to a
test and treat scenario.
Further efforts should be made to validate other detec-
tion tools. The choice of a specific diagnostic assay should
be governed by the objective of the activity and according
to the status of control [66]. As the accuracy of a given
diagnostic technique may vary significantly according to
schistosomiasis transmission level, tools should be
adapted when moving from morbidity control to elimin-
ation of infection. Moving toward the surveillance and
elimination phases requires more sensitive techniques
such as antibody detection. However, sero-diagnostics
tools for detection of schistosome infections require blood
sample collection (invasive) and access to affordable, high-
quality reagents [72]; all being limiting factors for their in-
tegration into large-scale national control programmes.
These limitations are amongst the reasons why only a few
countries have adopted antibody detection as a key strat-
egy in schistosomiasis diagnosis [73].
As transmission would be the measure of the true end
point of elimination, consideration should also be given to
the detection of natural schistosome infections in snails and
the measurement of the force of infection from cercariae.
Tackling reservoir hosts
Several species of schistosome are zoonotic and can nat-
urally be transmitted between humans and vertebrate
animals. Many domestic and wildlife animals act as res-
ervoir hosts for S. japonicum in Asia [74], and the in-
volvement of rodents in the transmission of S. mansonihas been demonstrated in Guadeloupe [75]. In Africa,
monkeys and baboons are known to be infected by S.
mansoni in their ecological areas [76]. However, their
potential reservoir role in the transmission of the disease
and as an impediment to schistosomiasis elimination
need to be further investigated. Although S. haemato-
bium is assumed human-specific, hybridization within S.
haematobium-group may constitute a real threat to
elimination, and a risk for outbreaks such as in Corsica
[77]. The complex population biology and transmission
ecology between humans and animal reservoirs affect
the success of control programmes, and magnifies the
challenges of elimination. Indeed, to eliminate schisto-
somiasis, one must not only eliminate infection in the
human population, but also prevent or eliminate trans-
mission from animal reservoirs [78].
The need for more funding
In Africa, schistosomiasis control programmes mainly
depend on external funds for MDA and often receive do-
nated drugs. If funding ceases, consolidation of achieve-
ments made is generally not sustainable, with rapid re-
emergence of schistosomiasis as a result. With the intensi-
fication of interventions towards schistosomiasis elimin-
ation, there is a need to increase funding to support
implementation of these interventions. More resources
should be mobilized to develop greater multisectoral col-
laboration in an effort to combat schistosomiasis. The
third WHO report on NTDs, “Investing to overcome the
global impact of neglected tropical diseases”, recognizes
the elimination and control of NTDs as a “litmus test” for
universal health coverage; and calls all endemic countries
to contribute by increasing their domestic investments to
scale-up interventions. NTD control needs to be become
an integral part of national health plans and budgets and
rely less on foreign aid and charity if it is to achieve uni-
versal health coverage [79].
Conclusion
It is clear that the landscape of schistosomiasis is changing
across SSA owing to the many ongoing interventions cur-
rently underway. In some regions, country progress may be
uneven but in some countries there are real prospects to
transition from control into interruption of transmission
and ultimately elimination settings. To manage this transi-
tion calls for reconsideration of some of the current diag-
nostic tools and the realignment of existing prevalence
treatment thresholds and their interpretation in defin-
ing areas where intervention is required. The key
challenge will be sustaining and expanding the
current donation of praziquantel and judging when it
is appropriate to move from MDA to selective treat-
ment, which will ensure that the health system is
adapted to respond to these new disease dynamics.
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